Fig. 6: Treatment of SAR131675 decreases the resiquimod-induced increase of TLR7/MyD88/IFN-α signaling pathway in the resiquimod-induced lupus nephritis. | Cell Death Discovery

Fig. 6: Treatment of SAR131675 decreases the resiquimod-induced increase of TLR7/MyD88/IFN-α signaling pathway in the resiquimod-induced lupus nephritis.

From: Inhibition of VEGFR-3 by SAR131675 decreases renal inflammation and lymphangiogenesis in the murine lupus nephritis model

Fig. 6

Representative Western blot analysis of TLR7/MyD88/IFN-α protein expression from each experimental group of SAR131675 treatment in the resiquimod-induced LN. The graph shows the densitometric quantification of Western blot bands by ImageJ software. Expression levels are normalized to HSP90 or β-actin. Statistical significance was determined using one-way ANOVA followed by Tukey’s post-hoc test. Data are expressed as mean ± SD. ****P < 0.0001 versus each group. Control, vehicle-treated group; SAR, SAR131675-treated group; Lupus, resiquimod-treated group; Lupus+SAR, resiquimod and concomitantly SAR131675-treated group. HSP90 heat shock protein 90, IFN-α interferon-α, LN lupus nephritis, MyD88 myeloid differentiation primary response 88, TLR7 toll-like receptor 7.

Back to article page